akash.verma@cenmed.com
(732) 447-1115-
17451-1A cytotoxic illudin that is converted, intracellularly, to metabolites that cause a complete block of cell cycling at the G1-S phase interface, particularly in myeloid and T-lymphocyte leukemia cells (IC<sub>50</sub> = 6-11 nM). -
15103-250An asymmetric phospholipid that can interdigitate with equal length (symmetric) acyl chain phospholipids in bilayer membranes to potentially minimize the hydrophobic mismatch between acyl chains. -
14161-25A natural isoflavone which promotes the proliferation of bone marrow stromal cells and osteoblasts and suppresses bone turnover. -
15407-500A glucocorticoid steroid that activates the glucorcorticoid receptor with an EC<sub>50</sub> value of 12.4 nM reduces inflammation and has utility in inflammatory diseases, like asthma and inflammatory bowel disease may be abused by athletes. -
13644-50An anti-platelet aggregator (IC<sub>50</sub> = 180 µM, in vitro) that prolongs bleeding time significantly in a rodent model of thromboembolism at ,24 mg/kg, generates antioxidant and neuroprotective effects against kainic acid-induced -
17112-5A form of FAHFA in which oleic acid is esterified to 13-hydroxy stearic acid. -
15108-500A metabolite of a phosphotidylinositol ether lipid analog known to target the pleckstrin homology domain of Akt and to induce apoptosis in cancer cell lines with high levels of endogenous Akt activity. -
15094-50A phospholipid containing the tetramethylated long-chain (16:0) diphytanic acid inserted at the sn-1 and sn-2 positions. -
19315-10A hybrid of selenium and an NSAID that has been shown to reduce the viability of different cancer cell lines, particularly colorectal cancer (CRC) cells (IC<sub>50</sub> = 3.4 µM) inhibits the cell cycle in G1 and G2/M phases and induces -
20224-5A selective inhibitor of TAF1 bromodomain 2 (IC<sub>50</sub> = 2.1 µM) synergizes with (+)-JQ1 to inhibit the proliferation of THP-1 and H23 lung adenocarcinoma cells. -
19956-5A selective inhibitor of TAF1 bromodomain 2 (Kd = 1.8 µM IC<sub>50</sub> = 0.9 µM) synergizes with (+)-JQ1 to inhibit the proliferation of THP-1 and H23 lung adenocarcinoma cells. -
10009570-10A selective inhibitor of cytohesins, blocking human, mouse, and Drosophila cytohesins with IC50 values of 2.4 to 5.6 µM prevents cytohesin-dependent insulin signaling in HepG2 cells produces hepatic insulin resistance in mice.
